New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
05:59 EDTBLUEbluebird bio announces data from HGB-205 clinical study
bluebird bio on Saturday released initial clinical data from its HGB-205 clinical study of its LentiGlobin BB305 product candidate in beta-thalassemia major subjects. The company said the clinical update provided on two subjects treated in the prior LG001 Study using the prior lentiviral HPV569 product candidate; Subject 3 remains blood transfusion independent 72 months after being transplanted with the lentiviral HPV569 product candidate; Subjects 3 and 4 are producing 2.7 g/dL and 0.4 g/dL of therapeutic beta A-T87Q-globin post-transplant, respectively; No drug product related adverse events were reported in the LG001 Study. The company sees reporting additional data from the HGB-205 Study and from our ongoing Northstar Study in late 2014.
News For BLUE From The Last 14 Days
Check below for free stories on BLUE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for BLUE

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use